FDA announced it has approved the use of tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
After 20 years of living with lymphoma, Lois Rosenblum knows firsthand the importance of a strong support system and advocating
for your health. Following an initial diagnosis of follicular lymphoma in 2002 and several disease transformations since then, she’s passionate about supporting the work that the Lymphoma Research Foundation (LRF) does to power cutting-edge research to treat and defeat lymphoma.
Clinical trials are important for advancing research and can provide patients with access to the most cutting-edge treatments. LRF Associate Director of Support Services and Helpline specialist, Izumi Nakano, answers some common questions about clinical trials to help better understand the process and what to think about when considering enrolling in one.
Rituximab (RITUXAN, Genentech, Inc.), a monoclonal antibody, has been approved in combination with chemotherapy for pediatric patients 6-18 months with previously untreated, advanced staged, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and Burkitt-like lymphoma (BLL).
The Lymphoma Research Foundation (LRF) encourages patients, survivors, and their caregivers to take information and questions back to their individual health care providers as a way of creating a dialogue and partnership about their lymphoma and treatment.
For more than 23 years, Marla Briskman faced her lymphoma—enduring five relapses and six different treatments. What gave her hope? Incredible treatment advancements and the support of family, friends, and her husband and caregiver, Rickey.
A lymphoma diagnosis not only affects the patient, but their caregivers too. LRF Scientific Advisory Board member, Thomas M. Habermann, MD shares some helpful strategies on how to help cope with some of the pressures of caregiving.